News | May 14, 2009

CMS Opens NCD for PET-FDG used in Cervical Cancer Staging

May 14, 2009 -On May 8, 2009, CMS opened the reconsideration of the National Coverage Determination (NCD) on Positron Emission Tomography (FDG). The requestors have asked CMS to reconsider the NCD and broaden national coverage of FDG-PET (without CED restrictions) for the staging of cervical cancer (i.e. in those women who have been diagnosed with cervical cancer but who do not otherwise meet the coverage criteria). The requestors also ask that the use of FDG-PET be nationally noncovered to make the diagnosis of cervical cancer, as this imaging is not helpful to make the initial diagnosis.

Currently, Medicare covers, nationally, FDG-PET when it is used by the beneficiary’s physician to guide the subsequent management of cervical cancer in women who have undergone anticancer treatment. For example, FDG-PET is covered to determine whether or not the cancer has responded to treatment or to determine if the patient's symptoms are being caused by a recurrence or spreading of the cancer.

Additionally, FDG-PET is nationally covered for some uses in women diagnosed with cervical cancer who have not yet received anticancer treatment. Specifically, FDG-PET imaging is covered as an adjunct test for the detection of pre-treatment metastasis (i.e., staging) in newly diagnosed cervical cancers following conventional imaging that is negative for extra-pelvic metastasis.

Medicare coverage of all other uses of FDG-PET related to cervical cancer is restricted to beneficiaries who are enrolled in a prospective clinical study under a CED program, like NOPR.

Follow the link to see the NCA Tracking Sheet for Positron Emission Tomography (FDG) for Cervical Cancer (CAG-00181R2)

There will be a public comment period open from 5/8/2009 – 6/7/2009. To submit comments, go to this link:

CMS considers all public comments, and is particularly interested in clinical studies and other scientific information relevant to the technology under review.

CMS expects to release the proposed decision memo on November 8, 2009 and finalize their decision by February 6, 2010.

For more information: and

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init